S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Will Nvidia Be the Lifeline Intel Desperately Needs?
Here’s Why Disney’s MCU is Sinking in Quicksand
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Stock market today: Asian stocks rise after Wall St retreats on concern economy weakening
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
NYSE:BVS

Bioventus (BVS) Stock Forecast, Price & News

$2.70
-0.26 (-8.78%)
(As of 06/5/2023 ET)
Compare
Today's Range
$2.70
$3.04
50-Day Range
$0.93
$2.96
52-Week Range
$0.80
$9.90
Volume
531,127 shs
Average Volume
1.13 million shs
Market Capitalization
$211.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Bioventus MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
103.7% Upside
$5.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$2.99 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.15) to $0.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

719th out of 986 stocks

Surgical & Medical Instruments Industry

72nd out of 96 stocks


BVS stock logo

About Bioventus (NYSE:BVS) Stock

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Receive BVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter.

BVS Stock News Headlines

Bioventus Inc. (NYSE:BVS) CEO Buys $291,250.00 in Stock
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Recap: Bioventus Q1 Earnings
Bioventus Reports First Quarter Financial Results
7BVS : Earnings Preview: Bioventus
Bioventus (BVS) Set to Announce Earnings on Thursday
Bioventus Announces CEO Leadership Change
Bioventus (NYSE:BVS) PT Lowered to $5.00
Here’s Why Bioventus (BVS) Declined in Q4
See More Headlines

BVS Price History

BVS Company Calendar

Last Earnings
3/31/2023
Today
6/05/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Phone
N/A
Fax
N/A
Employees
1,120
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+98.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-158,700,000.00
Pretax Margin
-67.04%

Debt

Sales & Book Value

Annual Sales
$512.12 million
Cash Flow
$1.55 per share
Book Value
$4.37 per share

Miscellaneous

Free Float
71,933,000
Market Cap
$216.81 million
Optionable
Not Optionable
Beta
0.23

Key Executives

  • Mr. Kenneth M. Reali (Age 56)
    CEO & Director
    Comp: $1.77M
  • Mr. Mark SingletonMr. Mark Singleton (Age 53)
    Sr. VP, CFO & Principal Accounting Officer
  • Mr. Anthony James
    VP of Operations and Quality
  • Ms. Alessandraa Pavesio (Age 55)
    Sr. VP & Chief Science Officer
  • Mr. David Crawford
    VP of Investor Relations & Treasurer
  • Mr. Anthony D'Adamio (Age 61)
    Sr. VP, Gen. Counsel & Corp. Sec.
  • Ms. Katrina J. Church (Age 60)
    Sr. VP & Chief Compliance Officer
  • Mr. Jeff Welch
    VP of Bus. Devel.
  • Mr. Christopher K. Yamamoto
    Sr. VP of Corp. Devel. & Strategy
  • Mr. Leigh Ann Stradford
    Sr. VP & Chief HR Officer













BVS Stock - Frequently Asked Questions

Should I buy or sell Bioventus stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bioventus in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BVS, but not buy additional shares or sell existing shares.
View BVS analyst ratings
or view top-rated stocks.

What is Bioventus' stock price forecast for 2023?

5 Wall Street research analysts have issued twelve-month price targets for Bioventus' stock. Their BVS share price forecasts range from $5.00 to $6.00. On average, they anticipate the company's share price to reach $5.50 in the next year. This suggests a possible upside of 98.6% from the stock's current price.
View analysts price targets for BVS
or view top-rated stocks among Wall Street analysts.

How have BVS shares performed in 2023?

Bioventus' stock was trading at $2.61 at the beginning of 2023. Since then, BVS stock has increased by 6.1% and is now trading at $2.77.
View the best growth stocks for 2023 here
.

When is Bioventus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our BVS earnings forecast
.

How were Bioventus' earnings last quarter?

Bioventus Inc. (NYSE:BVS) issued its earnings results on Friday, March, 31st. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.05 by $0.11. The company earned $125.83 million during the quarter, compared to analysts' expectations of $134.09 million. Bioventus had a negative net margin of 55.77% and a positive trailing twelve-month return on equity of 0.49%.

When did Bioventus IPO?

(BVS) raised $126 million in an IPO on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO.

What is Bioventus' stock symbol?

Bioventus trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVS."

Who are Bioventus' major shareholders?

Bioventus' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (2.49%), Geode Capital Management LLC (0.82%), State Street Corp (0.69%), Strs Ohio (0.42%), Stephens Inc. AR (0.40%) and Charles Schwab Investment Management Inc. (0.30%). Insiders that own company stock include Anthony D'adamio, Anthony P Bihl III, John A Bartholdson, John Nosenzo, Katrina J Church, Kenneth Michael Reali, Mark Leonard Singleton and William A Hawkins.
View institutional ownership trends
.

How do I buy shares of Bioventus?

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bioventus' stock price today?

One share of BVS stock can currently be purchased for approximately $2.77.

How much money does Bioventus make?

Bioventus (NYSE:BVS) has a market capitalization of $216.81 million and generates $512.12 million in revenue each year. The company earns $-158,700,000.00 in net income (profit) each year or ($4.63) on an earnings per share basis.

How many employees does Bioventus have?

The company employs 1,120 workers across the globe.

How can I contact Bioventus?

Bioventus' mailing address is 4721 EMPEROR BOULEVARD SUITE 100, DURHAM NC, 27703. The official website for the company is www.bioventus.com. The company can be reached via email at investor.relations@bioventus.com.

This page (NYSE:BVS) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -